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Abstract
Objective—To assess the feasibility of a randomized placebo controlled trial (RCT) of blood
pressure (BP) management for extremely preterm infants.
Study design—This was a prospective pilot RCT of infants 230/7 – 266/7 weeks gestation who
had protocol-defined low BP in the first 24 postnatal hours. Enrolled infants were administered a
study infusion (dopamine or placebo) and a study syringe medication (hydrocortisone or placebo).
© 2012 Mosby, Inc. All rights reserved.
Contact Information for corresponding author Beau Batton, MD, Southern Illinois University School of Medicine (current affiliation),
Department of Pediatrics, Division of Neonatology, P.O. Box 19676, Springfield, Illinois 62794, Phone: 217-757-6428, Fax:
217-757-6844, bbatton@siumed.edu.
*List of members of Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network
is available at www.jpeds.com (Appendix).
The authors declare no conflicts of interest.
The National Institutes of Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development
(NICHD) provided grant support, including funding from the Best Pharmaceuticals for Children Act, for the Neonatal Research
Network’s Early Blood Pressure Pilot Study. Data collected at participating sites of the NICHD Neonatal Research Network were
transmitted to RTI International, the data coordinating center (DCC) for the network, which stored, managed and analyzed the data for
this study.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Pediatr. Author manuscript; available in PMC 2013 July 01.
Published in final edited form as:













Results—Of the 366 infants screened, 119 (33%) had low BP, 58 (16%) met all entry criteria,
and 10 (3%) were enrolled. 161 (44%) infants were ineligible because they received early
indomethacin. Only 17% of eligible infants were enrolled. Problems with consent included
insufficient time, parent unavailability, and physician unwillingness to enroll critically ill infants.
Two infants were withdrawn from the study due to the potential risk of intestinal perforation with
simultaneous administration of hydrocortisone and indomethacin.
Conclusions—This pilot RCT was not feasible due to low eligibility and consent rates. An RCT
of BP management for extremely preterm infants may require a waiver of consent for research in
emergency care. The frequent use of early indomethacin and the associated risk of intestinal
perforation when used with hydrocortisone may limit future investigations to only inotropic
medications.
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The critical condition of most extremely preterm infants in the first week makes
identification of a stable population on which to base “normal” blood pressure (BP) data
difficult.1–4 Uncertainty regarding the acceptable range of BP also makes deciding when to
institute therapy for low BP challenging and contributes to the wide variation in BP
management for preterm infants.5–9 Antihypotensive therapies may raise BP,10,11 but there
is little evidence to suggest infants benefit from them4,6, 12–16 and they may all be
harmful.9,16–24 Compared with untreated infants of a similar gestational age (GA), preterm
infants given an antihypotensive therapy have higher rates of death,12,24–27 cognitive
impairment,26,27 deafness,25 and cerebral palsy.26 These poor outcomes may be due to the
etiology of low BP, associated organ hypoperfusion, the treatment of low BP, or a
combination of these and other factors.
There are inherent challenges with studying urgent therapeutic interventions shortly after
birth in this highly vulnerable patient population. First, the consent process is difficult. An
antenatal approach may result in a high number of mothers approached for every infant
enrolled28 and place an undue burden on women already in a stressful situation. Postnatal
consent is difficult by the very short time window available, the high degree of stress parents
experience after extremely preterm infant birth, and the frequent administration of
medications which affect maternal cognition. Second, clinicians may not have sufficient
equipoise to enroll infants in an RCT investigating low BP management because there is not
a well established definition of low BP in this population and opinions vary significantly.6–8
Lastly, as with any RCT, infants administered study medications may have worse outcomes
than those given a placebo because there is a lack of drug safety data within this population.
The lack of large randomized placebo controlled trials (RCT) investigating the use of
antihypotensive therapies for preterm infants with low BP in the immediate postnatal period
is partially due to the challenges with performing such a trial. This feasibility study of BP
management for extremely preterm infants in the immediate postnatal period was performed
to assess whether adequate enrollment in an RCT could be achieved using traditional
consent mechanisms within a reasonable time frame and without increased risk of morbidity
or mortality in any of the study arms.
Methods
Inborn infants born 230/7 – 266/7 weeks GA at one of seven collaborating Eunice Kennedy
Shriver National Institute of Child Health and Human Development Neonatal Research
Network (NRN) centers were eligible for this study if they had protocol-defined low BP.
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Exclusion criteria included a major birth defect, a decision to withhold or withdraw care,
absence of an umbilical arterial catheter (UAC), or recipt of >20 ml/kg of fluid boluses,
indomethacin, or ibuprofen prior to enrollment. Informed parental consent was obtained
prior to enrollment. This occurred either antenatally or postnatally (before or after the infant
reached study eligibility criteria). Reasons for enrollment failure of eligible infants were
tracked. This study was approved by the Institutional Review Board at each participating
center.
After the correction of hypothermia, anemia, hypoglycemia, and any mechanical cause of
low BP, infants were eligible if they had at least two protocol-defined low mean arterial
blood pressure (MAP) values (Table I) in the first 24 hours which each met the following
criteria: 1) obtained from a UAC with a good wave pattern; 2) not related to medication
administration, handling of the infant, technical error, or tracheal suction; 3) lasted at least
60 seconds and; 4) low MAP values occurred at least 15 minutes, but no more than six
hours, apart. Protocol-defined low BP was derived from previous studies and consensus
opinion among the NRN centers to reflect the rise in BP noted with advancing postnatal age
and differences in BP values which occur with invasive versus oscillographic
measurements.1–3,8,12–14,29 Prior to study entry, perceived low BP or poor perfusion could
be managed at the discretion of the clinical care team with only a fluid bolus of ≤20 ml/kg.
This was a double-blinded pilot RCT (ClinicalTrials.gov#NCT00874393). Enrolled infants
were randomized to receive a study infusion (dopamine or placebo) and a study syringe
medication (hydrocortisone or placebo) so that they were allocated to one of four groups: 1)
dopamine/placebo; 2) dopamine/hydrocortisone; 3) placebo/placebo; 4) placebo/
hydrocortisone. This 2 X 2 factorial design was chosen because dopamine and
hydrocortisone are the most common inotrope and glucocorticoid used for low BP in this
population,8 a significant drug-drug interaction between the two medications was unlikely,
and the effect of the two medications used in combination on infant outcomes was clinically
relevant. A placebo/placebo study arm was included because these medications are
potentially harmful, not all infants with low BP receive antihypotensive therapy, and there is
uncertainty about the clinical efficacy of these medications in this patient
population.4,6,9,12–24
The study infusion was begun at 6 mcg/kg/min of dopamine (or placebo volume equivalent)
and increased as often as every 20 minutes to a maximum rate of 15 mcg/kg/min. Specific
BP criteria for weaning and escalating the study infusion were implemented. The study
infusion was stopped when specific BP criteria were achieved or the infant reached the 96th
postnatal hour. Seven doses of the study syringe medication were given: an initial dose of 1
mg/kg hydrocortisone (or placebo volume equivalent) followed by six doses of 0.5 mg/kg
every twelve hours. If pre-specified study exit criteria were met, open-label antihypotensive
therapy was permitted and the clinical care team was notified as to whether or not the infant
received dopamine and/or hydrocortisone. The primary outcome was the successful
enrollment of 60 infants within one year with a protocol deviation rate of ≤20%. This
sample size was chosen to approximate the rate of enrollment for an appropriately powered
RCT at all NRN centers over three years and the pilot study was conducted at a subset of
network centers to conserve resources while assessing feasibility. Participating centers had
experience in conducting RCTs, a principal investigator with publications investigating
preterm infant hemodynamics or antihypotensive therapies, and a neonatal group committed
to making every effort to complete the study. Protocol deviations included discontinuation
of study medications or the use of open-label antihypotensive therapies outside of study
protocol, and failure to administer the assigned study medications. Enrolled infants were
randomized from a pre-specified sequence allocated by center and administered by an
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investigational pharmacist. Only the investigational pharmacist was aware of assigned
medications.
Results
From December 3, 2009 – December 3, 2010, there were 366 inborn infants 23 – 26 weeks
GA admitted to the NICU of a participating NRN center (Figure). Fifty-eight (16%) infants
were eligible for the study and ten (3%) were enrolled. There were 339 (93%) infants born
to mothers who received at least one dose of a glucocorticoid prior to delivery, a UAC was
placed in 307 (84%) infants, and 119 (33%) infants had protocol-defined low BP. Due to
low recruitment, mid-way through the study a seventh center was added and the inclusion
criteria were adjusted to allow for study entry without a UAC.
Antenatal consent was sought from 39 women and obtained for four infants born at 23 – 26
weeks GA and postnatal informed consent was obtained prior to eligibility for 17 infants.
None of these infants met study eligibility criteria. The parents of 20 of the 58 (34%)
eligible infants were not approached for consent. For 13 (65%) of these infants, the
attending neonatologist was unwilling to consider enrollment in an RCT due to the infant’s
critical condition or because s/he felt the infant was deteriorating too quickly to wait for
consent. In seven (35%) cases, one or both parents were not available to provide consent or
the mother was unable to consent due to medications affecting her cognition. Of the 38
eligible infants whose parents were approached for consent, 10 (26%) granted consent and
their infant was enrolled, 23 (61%) parents refused consent, three (8%) parents could not
make a timely decision regarding consent, and in two (5%) cases the neonatologist chose to
provide open-label therapy for low BP while research personnel were attempting to obtain
consent.
The outcomes of the ten enrolled infants are presented in Table II. None of the infants
received open-label antihypotensive therapy in the first postnatal week. Although the two
infant deaths occurred in the placebo/placebo group, the time of death was distant from
enrollment (day 20 for patient six and day 62 for patient seven). Two protocol deviations
occurred when the study syringe medication was stopped without meeting exit criteria. The
reason for study withdrawal cited in both cases was the risk of intestinal perforation with the
possible simultaneous administration of hydrocortisone and indomethacin (administered to
facilitate closure of the ductus arteriosus). Of the 48 eligible infants not enrolled in the
study, 41 (85%) received at least one therapy for low BP, 34 (71%) received ≥20 ml/kg in
fluid boluses, 31 (65%) dopamine, 11 (23%) hydrocortisone, eight (17%) dobutamine, and
one (2%) epinephrine.
Discussion
In this pilot study to assess the feasibility of an RCT of BP management in extremely
preterm infants, a low percentage of infants met all eligibility criteria, few eligible infants
were enrolled, and a protocol deviation occurred in 20% of enrolled infants. The study did
not achieve its primary objective. Several major factors hindered success, including fewer
than anticipated infants with low BP, high rates of early indomethacin administration,
difficulty obtaining informed consent, and a lack of physician equipoise. Previous studies
suggested approximately half of the infants in this population have low BP,1–7,12–14,16,25
however, only one-third of screened infants had protocol-defined low BP. It is unlikely this
was due to a different definition of low BP as the criteria used for this study were similar to
those of previous reports.4,8,12–14 The high rate of antenatal glucocorticoid administration in
this study population (93%) may have improved cardiovascular transition because these
medications have been shown to decrease the incidence of low BP in preterm infants.30
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The most common exclusion criterion in this study was prior administration of indomethacin
(44% of screened infants). An unanticipated change in practice at two participating centers
early in the study led to the routine, but not universal, use of prophylactic indomethacin for
IVH prevention in all infants born ≤28 weeks GA. In addition, two infants were withdrawn
from the study when indomethacin was begun due to concern that the possible concomitant
use of hydrocortisone and indomethacin significantly increases the risk of gastrointestinal
perforation.22,23 Therefore, despite its common use in practice,6,9 it may be difficult to
include hydrocortisone in an RCT of early BP management.
Difficulties with the consent process resulted in parental consent being successfully obtained
for only 17% of eligible infants. Obstacles included the inefficiency of obtaining antenatal
consent, the brief window for obtaining postnatal consent, and family stress surrounding
extremely preterm infant birth. Antenatal consent was sought from 39 women and
successfully obtained for four infants born within the study GA range, but none of these
infants met all eligibility criteria. This is consistent with a previous RCT within the NRN in
which antenatal consent was required because infants were enrolled in the delivery room at
birth.28 In that study, over five women were approached for every infant enrolled.
Extrapolating those data to the current study suggests over 35 women would need to be
approached prior to delivery for every infant enrolled in an RCT. For 17 infants, postnatal
consent was obtained before the infant had low BP. None of these infants met study
eligibility criteria, demonstrating the considerable investment of time and effort required to
consent parents before entry criteria are met. However, once criteria are met, the window for
obtaining consent is short, and several factors may preclude doing so quickly. The birth of
an extremely preterm infant is always stressful for parents, and the mother may be receiving
medications which interfere with informed consent. In addition, most centers required
consent from both parents, but there were instances when paternity was not certain or the
father was not immediately available. These factors make obtaining postnatal informed
consent so difficult that an RCT of early BP management may not be possible without a
waiver of consent as is permitted in the conduct of research of emergency conditions under
the United States Food and Drug Administration Code of Federal Regulations
#21CFR50.24. Specific criteria which must be met for this waiver include but are not
limited to: study subjects are in a life threatening situation; study participation may directly
benefit subjects; investigation could not practicably be carried out without a waiver; an
Institutional Review Board approved informed consent process is used when feasible.
Although few studies have been conducted on newborn preterm infants using such a waiver,
this approach may allow for enrollment of a broader cohort of infants with less risk of a
selection bias.28 Furthermore, a waiver of consent leaves the option for a deferred
information sharing process at which time parents may choose to have their infant opt-out of
the study. This seems ethically justifiable given that both treatment and non-intervention are
common clinical approaches to this problem.4,6,712–14
Physician equipoise is another potential barrier to adequate enrollment without selection
bias: 22% of eligible infants were not approached at physician request, and two infants were
given open-label anti-hypotensive therapy while research personnel were attempting to
obtain consent. Furthermore, 85% of eligible infants not enrolled in the study received anti-
hypotensive therapy. Although it may be inappropriate to withhold such treatments from
infants with clinical or biochemical evidence of poor perfusion, studies suggest this occurs
in only a small subset of infants with low BP.12–14 The wide variation in BP management
for this population7,16 exists in part because there are insufficient data to support a single
approach. In the absence of evidence-based guidelines, clinicians make decisions based on
previous experience, training, and personal interpretation of the literature, resulting in
significant and variable bias. This may hinder the success of an RCT of BP management in
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this population such that a strong commitment to adhere to study protocol should be secured
from a large group of neonatologists prior to study initiation.
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Flow diagram of infants. GA = gestational age; BP = blood pressure
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